Investments
20Portfolio Exits
8About S-Cubed Capital
S-Cubed Capital manages a globally diversified investment portfolio with the goal of achieving superior, long term, risk-adjusted returns. The investment portfolio participates in a variety of asset classes: public global equities, fixed income, absolute return, private equity, and real assets. The relative weighting towards each asset class is reviewed on a consistent basis and is adjusted as required to meet long term return objectives.
S-Cubed Capital Headquarter Location
2061 Avy Avenue 1st Floor
Menlo Park, California, 94025,
United States
650-234-8224
Latest S-Cubed Capital News
Nov 10, 2020
Back to HomeBOSTON, MA, Decibel Therapeutics has closed an oversubscribed Series D financing led by OrbiMed, which raised $82.2M.Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, has closed an oversubscribed Series D financing, which raised $82.2M.The round was led by OrbiMed, with new investments from BlackRock Health Sciences, Casdin Capital, Janus Henderson, Samsara BioCapital and Surveyor Capital (a Citadel company).Existing investors also participated in the financing, including Foresite Capital, GV, S-Cubed Capital, Sobrato Capital, SR One, Third Rock Ventures and other institutional investors.Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
S-Cubed Capital Investments
20 Investments
S-Cubed Capital has made 20 investments. Their latest investment was in Decibel Therapeutics as part of their Series D on November 11, 2020.
S-Cubed Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/9/2020 | Series D | Decibel Therapeutics | $82M | No | 17 | |
7/21/2020 | Series F | Innovium | $170M | No | 10 | |
1/9/2020 | Series C | Pliant Therapeutics | $100M | No | 4 | |
7/9/2019 | Series D | |||||
9/5/2018 | Series D - II |
Date | 11/9/2020 | 7/21/2020 | 1/9/2020 | 7/9/2019 | 9/5/2018 |
|---|---|---|---|---|---|
Round | Series D | Series F | Series C | Series D | Series D - II |
Company | Decibel Therapeutics | Innovium | Pliant Therapeutics | ||
Amount | $82M | $170M | $100M | ||
New? | No | No | No | ||
Co-Investors | |||||
Sources | 17 | 10 | 4 |
S-Cubed Capital Portfolio Exits
8 Portfolio Exits
S-Cubed Capital has 8 portfolio exits. Their latest portfolio exit was Innovium on August 03, 2021.
S-Cubed Capital Team
2 Team Members
S-Cubed Capital has 2 team members, including current Managing Partner, Mark Stevens.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.